Integration of molecular cancer classification and next-generation sequencing to identify metastatic patients eligible for PARP inhibitors.

e15080Background: Olaparib, rucaparib, and niraparib are 3 poly-ADP-ribose polymerase inhibitors (PARPi) approved by the FDA for ovarian, breast, pancreatic, prostate, fallopian tube and peritoneal...